Keynote review: phosphodiesterase-4 as a therapeutic target (Q28279487)

Cyclic nucleotide research -- still expanding after half a century

Europe PubMed Central

title

Keynote review: phosphodiesterase-4 as a therapeutic target (English)

0 references

Miles D Houslay

1

0 references

author name string

Peter Schafer

series ordinal

2

0 references

Kam Y J Zhang

series ordinal

3

0 references

language of work or name

English

0 references

publication date

15 November 2005

0 references

published in

Drug Discovery Today

0 references

volume

10

0 references

issue

22

0 references

page(s)

1503-19

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Localized effects of cAMP mediated by distinct routes of protein kinase A.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

PDE4D plays a critical role in the control of airway smooth muscle contraction

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Anti-Inflammatory Potential of the Selective Phosphodiesterase 4 InhibitorN-(3,5-Dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic Acid Amide (AWD 12-281), in Human Cell Preparations

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Phosphodiesterase 4-selective inhibition: novel therapy for the inflammation of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4).

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

The potential of PDE4 inhibitors in respiratory disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identification and characterization of a novel PDE4D5 promoter

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Identification and characterization of PDE4A11, a novel, widely expressed long isoform encoded by the human PDE4A cAMP phosphodiesterase gene

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Expression of phosphodiesterase 4D (PDE4D) is regulated by both the cyclic AMP-dependent protein kinase and mitogen-activated protein kinase signaling pathways. A potential mechanism allowing for the coordinated regulation of PDE4D activity and expr

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1)

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Short term feedback regulation of cAMP in FRTL-5 thyroid cells. Role of PDE4D3 phosphodiesterase activation.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Myomegalin is a novel protein of the golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase family form a discrete module via electrostatic interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Conformational difference between PDE4 apoenzyme and holoenzyme

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species that exhibit distinct kinetics of inhibition by the antidepressant rolipram

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B. Consequences for rolipram inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Identification of a surface on the beta-propeller protein RACK1 that interacts with the cAMP-specific phosphodiesterase PDE4D5

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Crystal structure of phosphodiesterase 4D and inhibitor complex(1)

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Structural basis for the activity of drugs that inhibit phosphodiesterases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

TAPAS-1, a novel microdomain within the unique N-terminal region of the PDE4A1 cAMP-specific phosphodiesterase that allows rapid, Ca2+-triggered membrane association with selectivity for interaction with phosphatidic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Phosphodiesterase 4D and protein kinase a type II constitute a signaling unit in the centrosomal area

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

In addition to the SH3 binding region, multiple regions within the N-terminal noncatalytic portion of the cAMP-specific phosphodiesterase, PDE4A5, contribute to its intracellular targeting

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Phosphodiesterase 4D is required for beta2 adrenoceptor subtype-specific signaling in cardiac myocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with beta-arrestins

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Elevated cyclic AMP inhibits NF-kappaB-mediated transcription in human monocytic cells and endothelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Inhibition of the NF-kappaB transcriptional activity by protein kinase A.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

cAMP-induced Interleukin-10 promoter activation depends on CCAAT/enhancer-binding protein expression and monocytic differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Cyclic adenosine monophosphate-responsive elements are involved in the transcriptional activation of the human IL-10 gene in monocytic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Calcitonin gene-related peptide inhibits lipopolysaccharide-induced interleukin-12 release from mouse peritoneal macrophages, mediated by the cAMP pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Role of CFTR in airway disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

A macromolecular complex of beta 2 adrenergic receptor, CFTR, and ezrin/radixin/moesin-binding phosphoprotein 50 is regulated by PKA

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Protein kinase A associates with cystic fibrosis transmembrane conductance regulator via an interaction with ezrin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

E3KARP mediates the association of ezrin and protein kinase A with the cystic fibrosis transmembrane conductance regulator in airway cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

PDE4-regulated cAMP degradation controls the assembly of integrin-dependent actin adhesion structures and REF52 cell migration

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

The novel long PDE4A10 cyclic AMP phosphodiesterase shows a pattern of expression within brain that is distinct from the long PDE4A5 and short PDE4A1 isoforms.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Brain distribution of four rat homologues of the Drosophila dunce cAMP phosphodiesterase.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Results of a phase II study of the antidepressant effect of rolipram

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Inhibitors of Type IV Phosphodiesterases Reduce the Toxicity of MPTP in Substantia Nigra NeuronsIn Vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Vascular smooth muscle cell phenotype-dependent phosphodiesterase 4D short form expression: role of differential histone acetylation on cAMP-regulated function

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

The unique N-terminal domain of the cAMP phosphodiesterase PDE4D4 allows for interaction with specific SH3 domains

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Delineation of RAID1, the RACK1 interaction domain located within the unique N-terminal region of the cAMP-specific phosphodiesterase, PDE4D5.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903622-6

7 January 2021

10.1016/S1359-6446(05)03622-6

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

501927

501927

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference